Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 24;12(5):663-672.
doi: 10.1093/ckj/sfz046. eCollection 2019 Oct.

Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study

Insa M Schmidt  1 , Silvia Hübner  2 , Jennifer Nadal  3 , Stephanie Titze  2 , Matthias Schmid  3 , Barbara Bärthlein  4   5 , Georg Schlieper  6 , Thomas Dienemann  2 , Ulla T Schultheiss  7 , Heike Meiselbach  2 , Anna Köttgen  7 , Jürgen Flöge  6 , Martin Busch  8 , Reinhold Kreutz  1 , Jan T Kielstein  9 , Kai-Uwe Eckardt  2   10
Affiliations

Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study

Insa M Schmidt et al. Clin Kidney J. .

Abstract

Background: Patients with chronic kidney disease (CKD) bear a substantial burden of comorbidities leading to the prescription of multiple drugs and a risk of polypharmacy. However, data on medication use in this population are scarce.

Methods: A total of 5217 adults with an estimated glomerular filtration rate (eGFR) between 30 and 60 mL/min/1.73 m2 or an eGFR ≥60 mL/min/1.73m2 and overt proteinuria (>500 mg/day) were studied. Self-reported data on current medication use were assessed at baseline (2010-12) and after 4 years of follow-up (FU). Prevalence and risk factors associated with polypharmacy (defined as the regular use of five or more drugs per day) as well as initiation or termination of polypharmacy were evaluated using multivariable logistic regression.

Results: The prevalence of polypharmacy at baseline and FU was almost 80%, ranging from 62% in patients with CKD Stage G1 to 86% in those with CKD Stage G3b. The median number of different medications taken per day was eight (range 0-27). β-blockers, angiotensin-converting enzyme inhibitors and statins were most frequently used. Increasing CKD G stage, age and body mass index, diabetes mellitus, cardiovascular disease and a history of smoking were significantly associated with both the prevalence of polypharmacy and its maintenance during FU. Diabetes mellitus was also significantly associated with the initiation of polypharmacy [odds ratio (OR) 2.46, (95% confidence interval 1.36-4.45); P = 0.003].

Conclusion: Medication burden in CKD patients is high. Further research appears warranted to address the implications of polypharmacy, risks of drug interactions and strategies for risk reduction in this vulnerable patient population.

Keywords: GCKD study; chronic kidney disease; medication use; polypharmacy; prescription patterns.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Total number of medication intakes (prescribed and OTC) per patient at baseline (2010–12) (N = 5217).
FIGURE 2
FIGURE 2
Most commonly prescribed individual drugs at (A) baseline (2010–12, N = 5217) and (B) after FU (2014–16, N = 3128).
See this image and copyright information in PMC

References

    1. Zhang QL, Rothenbacher D.. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8: 117. - PMC - PubMed
    1. Khan UA, Garg AX, Parikh CR. et al. Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis. PLoS One 2013; 8: e71784. - PMC - PubMed
    1. Go AS, Chertow GM, Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305 - PubMed
    1. Titze S, Schmid M, Kottgen A. et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 2015; 30: 441–451 - PubMed
    1. Morin L, Johnell K, Laroche M-L. et al. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol 2018; 10: 289–298 - PMC - PubMed